Basel Medical Group (BMGL) Financials
A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 26, 2026; every other figure is from the SEC filings on this page. Not financial advice.
Newest figures come from the 20-F/A for FY2025, filed Mar 13, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the BMGL SEC filings page.
Basel Medical Group Ltd (BMGL) reported $8.9M in revenue for fiscal year 2025. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).
Financing currently supports the business more than operations do, while losses consume a large share of revenue and equity.
The clearest operating signal is the gap between a net loss of$8.4M and operating cash flow of-$3.2M : earnings and cash timing differ materially, although the supplied figures do not identify the exact bridge. Financing cash flow of$13.0M alongside investing cash flow of-$8.6M indicates that the period’s cash demands were met primarily outside operations.
The balance sheet is liability-heavy: liabilities equal
Current assets include
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed: here 5 of 6, with the others left out rather than counted as zero. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Basel Medical Group Ltd's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Not available for Basel Medical Group Ltd, so it is left out of the overall score, which averages the 5 of 6 dimensions that can be computed.
Basel Medical Group Ltd has a moderate D/E ratio of 0.54. This balance of debt and equity financing earns a leverage score of 59/100.
Basel Medical Group Ltd's current ratio of 1.31 indicates adequate short-term liquidity, earning a score of 34/100. The company can meet its near-term obligations, though with limited headroom.
Basel Medical Group Ltd's operations used $3.2M of cash, and capex of $438K added to the outflow, for a free cash flow shortfall of $3.6M. This results in a cash flow score of 6/100.
Basel Medical Group Ltd posts a -195.6% return on equity (ROE), meaning it loses $196 for every $100 of shareholders' equity. This results in a returns score of 2/100.
Basel Medical Group Ltd reported a net loss of $8.4M while operations used $3.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Basel Medical Group Ltd generated $8.9M in revenue in fiscal year 2025.
Basel Medical Group Ltd reported a net loss of $8.4M in fiscal year 2025.
Basel Medical Group Ltd earned -$0.45 per diluted share (EPS) in fiscal year 2025.
Not reported for fiscal year 2025.
Cash & Balance Sheet
Basel Medical Group Ltd recorded an outflow of $3.6M in free cash flow in fiscal year 2025, representing a cash shortfall after capex.
Basel Medical Group Ltd held $2.4M in cash against $2.3M in long-term debt as of fiscal year 2025.
Not reported for fiscal year 2025.
Margins & Returns
Basel Medical Group Ltd's net profit margin was -94.0% in fiscal year 2025, showing the share of revenue converted to profit.
Basel Medical Group Ltd's ROE was -195.6% in fiscal year 2025, measuring profit generated per dollar of shareholder equity.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
Capital Allocation
Basel Medical Group Ltd invested $438K in capex in fiscal year 2025, funding long-term assets and infrastructure.
Not reported for fiscal year 2025.
Not reported for fiscal year 2025.
BMGL Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F/A |
|---|---|
| Revenue | $8.9M |
| Interest Expense | $70K |
| Income Tax | -$328K |
| Net Income | -$8.4M |
| EPS (Basic) | -$0.51 |
| EPS (Diluted) | -$0.45 |
| Diluted Shares (Avg) | 19M |
Not reported in any period shown, so not listed: Cost of Revenue, Gross Profit, R&D Expenses, SG&A Expenses, Operating Income, EBITDA.
BMGL Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F/A |
|---|---|
| Total Assets | $14.7M |
| Current Assets | $10.5M |
| Cash & Equivalents | $2.4M |
| Inventory | $385K |
| Accounts Receivable | $7.5M |
| Goodwill | $8.1M |
| Total Liabilities | $10.4M |
| Current Liabilities | $8.0M |
| Non-Current Liabilities | $2.4M |
| Long-Term Debt | $2.3M |
| Total Equity | $4.3M |
| Retained Earnings | -$3.0M |
Not reported in any period shown, so not listed: Short-Term Investments, Long-Term Investments.
BMGL Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F/A |
|---|---|
| Operating Cash Flow | -$3.2M |
| Capital Expenditures | $438K |
| Free Cash Flow | -$3.6M |
| Investing Cash Flow | -$8.6M |
| Financing Cash Flow | $13.0M |
Not reported in any period shown, so not listed: Depreciation & Amortization, Stock-Based Compensation, Dividends Paid, Share Buybacks.
BMGL Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | FY2520-F/A |
|---|---|
| Net Margin | -94.0% |
| Return on Equity | -195.6% |
| Return on Assets | -56.9% |
| Current Ratio | 1.31 |
| Debt-to-Equity | 0.54 |
| Liabilities-to-Equity | 2.44 |
| Asset Turnover | 0.61 |
| FCF Margin | -40.6% |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin.
Similar Companies
Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.
| Company | Fiscal year | Revenue | Net income | Net margin | Market cap | Health score |
|---|---|---|---|---|---|---|
| Basel Medical Group Ltd BMGL | FY2025 | $8.9M | -$8.4M | -94.0% | $7.2M | 21/100 |
| Cryo-Cell International Inc. CCEL | FY2025 | $31.6M | -$2.4M | -7.7% | $40.4M | 26/100 |
| Concord Medical Services Holding Limited CCM | FY2025 | $65.9M | -$13.3M | -20.2% | $16.9M | 45/100 |
| American Shared Hospital Services AMS | FY2025 | $28.1M | -$1.6M | -5.5% | $8.3M | 37/100 |
| NewGenIvf Group Limited NIVF | FY2025 | $4.7M | $9.9M | N/A | $990K | 32/100 |
Where Basel Medical Group Ltd Ranks
Frequently Asked Questions
What is Basel Medical Group Ltd's annual revenue?
Basel Medical Group Ltd (BMGL) reported $8.9M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Basel Medical Group Ltd profitable?
No, Basel Medical Group Ltd (BMGL) reported a net loss of $8.4M in fiscal year 2025, with a net profit margin of -94.0%.
How much debt does Basel Medical Group Ltd have?
As of fiscal year 2025, Basel Medical Group Ltd (BMGL) had $2.4M in cash and equivalents against $2.3M in long-term debt.
What is Basel Medical Group Ltd's net profit margin?
Basel Medical Group Ltd (BMGL) had a net profit margin of -94.0% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
What is Basel Medical Group Ltd's return on equity (ROE)?
Basel Medical Group Ltd (BMGL) has a return on equity of -195.6% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Basel Medical Group Ltd's free cash flow?
Basel Medical Group Ltd (BMGL) recorded an outflow of $3.6M in free cash flow during fiscal year 2025. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Basel Medical Group Ltd's operating cash flow?
Basel Medical Group Ltd (BMGL) recorded an outflow of $3.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Basel Medical Group Ltd's total assets?
Basel Medical Group Ltd (BMGL) had $14.7M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Basel Medical Group Ltd's capital expenditures?
Basel Medical Group Ltd (BMGL) invested $438K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
What is Basel Medical Group Ltd's current ratio?
Basel Medical Group Ltd (BMGL) had a current ratio of 1.31 as of fiscal year 2025, which is considered adequate.
What is Basel Medical Group Ltd's debt-to-equity ratio?
Basel Medical Group Ltd (BMGL) had a debt-to-equity ratio of 0.54 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.
What is Basel Medical Group Ltd's liabilities-to-equity ratio?
Basel Medical Group Ltd (BMGL) had a liabilities-to-equity ratio of 2.44 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.
What is Basel Medical Group Ltd's return on assets (ROA)?
Basel Medical Group Ltd (BMGL) had a return on assets of -56.9% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Basel Medical Group Ltd's P/E ratio?
Basel Medical Group Ltd (BMGL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (FY2025). The market capitalization is $7.2M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
What is Basel Medical Group Ltd's price-to-sales ratio?
Basel Medical Group Ltd (BMGL) trades at 0.8x sales, its market capitalization divided by $8.9M revenue, FY2025. The market capitalization is $7.2M as of Oct 26, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.
Are Basel Medical Group Ltd's earnings high quality?
Basel Medical Group Ltd (BMGL) reported a net loss of $8.4M while operations used $3.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Basel Medical Group Ltd?
Basel Medical Group Ltd (BMGL) scores 21 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. For Basel Medical Group Ltd it averages the 5 of 6 dimensions that can be computed; the others are left out rather than counted as zero. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.